Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.

Hosoya K, Fujimoto D, Kawachi H, Sato Y, Kogo M, Nagata K, Nakagawa A, Tachikawa R, Hiraoka S, Kokubo M, Tomii K.

Cancer Chemother Pharmacol. 2019 Jun 14. doi: 10.1007/s00280-019-03885-4. [Epub ahead of print]

PMID:
31201490
2.

Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.

Fujimoto D, Yomota M, Sekine A, Morita M, Morimoto T, Hosomi Y, Ogura T, Tomioka H, Tomii K.

Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494-5. doi: 10.1016/j.lungcan.2019.06.001. [Epub ahead of print]

PMID:
31182249
3.

Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.

Kawachi H, Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K.

Anticancer Res. 2019 May;39(5):2561-2567. doi: 10.21873/anticanres.13378.

PMID:
31092453
4.

Novel lineage-specific transmembrane β-barrel proteins in the endoplasmic reticulum of Entamoeba histolytica.

Santos HJ, Imai K, Makiuchi T, Tomii K, Horton P, Nozawa A, Okada K, Tozawa Y, Nozaki T.

FEBS J. 2019 May 2. doi: 10.1111/febs.14870. [Epub ahead of print]

PMID:
31045303
5.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

6.

Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.

Kawachi H, Fujimoto D, Morimoto T, Hosoya K, Sato Y, Kogo M, Nagata K, Nakagawa A, Tachikawa R, Tomii K.

Invest New Drugs. 2019 Apr 1. doi: 10.1007/s10637-019-00770-y. [Epub ahead of print]

PMID:
30937690
7.

Pulmonary artery enlargement predicts poor outcome during acute exacerbations of fibrotic interstitial lung disease.

Kogo M, Otsuka K, Morimoto T, Nagata K, Nakagawa A, Tomii K.

Respirology. 2019 Mar 13. doi: 10.1111/resp.13504. [Epub ahead of print]

PMID:
30866125
8.

Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study.

Ito J, Nagata K, Morimoto T, Kogo M, Fujimoto D, Nakagawa A, Otsuka K, Tomii K.

J Thorac Dis. 2019 Jan;11(1):103-112. doi: 10.21037/jtd.2018.12.114.

9.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Erratum in: Lung Cancer. 2019 Jun;132:157-158.

10.

Prognostic significance of crazy paving ground grass opacities in non-HIV Pneumocystis jirovecii pneumonia: an observational cohort study.

Kumagai S, Arita M, Koyama T, Kumazawa T, Inoue D, Nakagawa A, Kaji Y, Furuta K, Fukui M, Tomii K, Taguchi Y, Tomioka H, Ishida T.

BMC Pulm Med. 2019 Feb 21;19(1):47. doi: 10.1186/s12890-019-0813-y.

11.

Altered Consciousness, Non-invasive Ventilation, and Hypoxemic Respiratory Failure: The Trident Question Unresolved - Reply.

Kogo M, Nagata K, Morimoto T, Ito J, Fujimoto D, Nakagawa A, Otsuka K, Tomii K.

Intern Med. 2019 Apr 15;58(8):1191-1192. doi: 10.2169/internalmedicine.1563-18. Epub 2019 Jan 10. No abstract available.

12.

Photodynamic therapy can prevent recurrence of lymphomatoid papulosis.

Arimatsu A, Tomii K, Fujiwara H, Hasegawa G, Shigehara Y, Tachibana T.

Photodiagnosis Photodyn Ther. 2019 Mar;25:334-335. doi: 10.1016/j.pdpdt.2019.01.007. Epub 2019 Jan 6. No abstract available.

PMID:
30625399
13.

Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.

Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K.

Anticancer Res. 2018 Dec;38(12):6891-6895. doi: 10.21873/anticanres.13065.

PMID:
30504406
14.

Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20.

PMID:
30468872
15.

Salvage Pulmonary Operations Following Stereotactic Body Radiotherapy for Small Primary and Metastatic Lung Tumors: Evaluation of the Operative Procedures.

Hamakawa H, Takahashi Y, Sakanoue I, Saito T, Date N, Tomii K, Katakami N, Imagunbai T, Kokubo M.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818807431. doi: 10.1177/1533033818807431.

16.

Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study.

Akamatsu H, Koh Y, Ozawa Y, Fujimoto D, Hata A, Katakami N, Tomii K, Shimokawa T, Yamamoto N.

Clin Lung Cancer. 2018 Nov;19(6):e871-e874. doi: 10.1016/j.cllc.2018.08.001. Epub 2018 Aug 22.

17.

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.

Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP.

Nat Commun. 2018 Aug 10;9(1):3198. doi: 10.1038/s41467-018-05626-2.

18.

Compound-protein interaction prediction with end-to-end learning of neural networks for graphs and sequences.

Tsubaki M, Tomii K, Sese J.

Bioinformatics. 2019 Jan 15;35(2):309-318. doi: 10.1093/bioinformatics/bty535.

PMID:
29982330
19.

Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.

Kawachi H, Fujimoto D, Morimoto T, Ito M, Teraoka S, Sato Y, Nagata K, Nakagawa A, Otsuka K, Tomii K.

Clin Lung Cancer. 2018 Sep;19(5):e721-e734. doi: 10.1016/j.cllc.2018.05.014. Epub 2018 May 26.

PMID:
29934133
20.

Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301).

Atagi S, Mizusawa J, Ishikura S, Takahashi T, Okamoto H, Tanaka H, Goto K, Nakagawa K, Harada M, Takeda Y, Nogami N, Fujita Y, Kasai T, Kishi K, Sawa T, Takeda K, Tomii K, Satouchi M, Seto T, Ohe Y.

Clin Lung Cancer. 2018 Sep;19(5):e619-e627. doi: 10.1016/j.cllc.2018.04.018. Epub 2018 May 5.

PMID:
29887243
21.

Erratum: AIG1 affects in vitro and in vivo virulence in clinical isolates of Entamoeba histolytica.

Nakada-Tsukui K, Sekizuka T, Sato-Ebine E, Escueta-de Cadiz A, Ji DD, Tomii K, Kuroda M, Nozaki T.

PLoS Pathog. 2018 May 31;14(5):e1007091. doi: 10.1371/journal.ppat.1007091. eCollection 2018 May. Erratum in: PLoS Pathog. 2018 Aug 17;14(8):e1007258.

22.

Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.

Fujimoto D, Sato Y, Morimoto T, Uehara K, Ito M, Otsuka K, Nagata K, Sakanoue I, Hamakawa H, Nakagawa A, Takahashi Y, Imai Y, Tomii K.

Clin Lung Cancer. 2018 Sep;19(5):e667-e673. doi: 10.1016/j.cllc.2018.04.012. Epub 2018 May 5.

PMID:
29844002
23.

The clinical practice of high-flow nasal cannula oxygen therapy in adults: A Japanese cross-sectional multicenter survey.

Ito J, Nagata K, Sato S, Shiraki A, Nishimura N, Izumi S, Tachikawa R, Morimoto T, Tomii K.

Respir Investig. 2018 May;56(3):249-257. doi: 10.1016/j.resinv.2018.02.002. Epub 2018 Mar 10.

PMID:
29773297
24.

Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.

Hirabayashi R, Fujimoto D, Satsuma Y, Hirabatake M, Tomii K.

Invest New Drugs. 2018 Oct;36(5):952-954. doi: 10.1007/s10637-018-0608-7. Epub 2018 May 2.

PMID:
29721756
25.

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2.

PMID:
29656747
26.

Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy.

Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Shintani A, Fujisawa T, Suda T, Arita M, Baba T, Ichikado K, Inoue Y, Kishi K, Kishaba T, Nishiyama O, Ogura T, Tomii K, Homma S.

PLoS One. 2018 Mar 28;13(3):e0193608. doi: 10.1371/journal.pone.0193608. eCollection 2018.

27.

AIG1 affects in vitro and in vivo virulence in clinical isolates of Entamoeba histolytica.

Nakada-Tsukui K, Sekizuka T, Sato-Ebine E, Escueta-de Cadiz A, Ji DD, Tomii K, Kuroda M, Nozaki T.

PLoS Pathog. 2018 Mar 19;14(3):e1006882. doi: 10.1371/journal.ppat.1006882. eCollection 2018 Mar. Erratum in: PLoS Pathog. 2018 May 31;14 (5):e1007091.

28.

Identification of new abscisic acid receptor agonists using a wheat cell-free based drug screening system.

Nemoto K, Kagawa M, Nozawa A, Hasegawa Y, Hayashi M, Imai K, Tomii K, Sawasaki T.

Sci Rep. 2018 Mar 9;8(1):4268. doi: 10.1038/s41598-018-22538-9.

29.

Parallelization of MAFFT for large-scale multiple sequence alignments.

Nakamura T, Yamada KD, Tomii K, Katoh K.

Bioinformatics. 2018 Jul 15;34(14):2490-2492. doi: 10.1093/bioinformatics/bty121.

30.

Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.

Sato Y, Fujimoto D, Uehara K, Kawachi H, Nagata K, Nakagawa A, Otsuka K, Sakanoue I, Hamakawa H, Takahashi Y, Imai Y, Tomii K.

Anticancer Res. 2018 Mar;38(3):1401-1405.

PMID:
29491064
31.

What Is the Impact of Mildly Altered Consciousness on Acute Hypoxemic Respiratory Failure with Non-invasive Ventilation?

Kogo M, Nagata K, Morimoto T, Ito J, Fujimoto D, Nakagawa A, Otsuka K, Tomii K.

Intern Med. 2018 Jun 15;57(12):1689-1695. doi: 10.2169/internalmedicine.9355-17. Epub 2018 Feb 9.

32.

Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.

Ogawa K, Ito J, Fujimoto D, Morita M, Yoshizumi Y, Ariyoshi K, Tomii K, Katakami N.

Invest New Drugs. 2018 Jun;36(3):509-512. doi: 10.1007/s10637-018-0561-5. Epub 2018 Jan 16.

PMID:
29340837
33.

Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial.

Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T, Tokioka F, Chohnabayashi N, Watanabe A, Sato S, Tomii K.

Ann Am Thorac Soc. 2018 Apr;15(4):432-439. doi: 10.1513/AnnalsATS.201706-425OC.

PMID:
29283682
34.

Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.

Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H.

Anticancer Res. 2018 Jan;38(1):559-563.

PMID:
29277824
35.

Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.

Fujimoto D, Sato Y, Uehara K, Ishida K, Fukuoka J, Morimoto T, Kawachi H, Mori R, Ito M, Teraoka S, Nagata K, Nakagawa A, Otsuka K, Imai Y, Tomii K.

J Thorac Oncol. 2018 Mar;13(3):377-386. doi: 10.1016/j.jtho.2017.11.123. Epub 2017 Dec 9.

36.

Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.

Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H.

Cancer Chemother Pharmacol. 2018 Feb;81(2):333-337. doi: 10.1007/s00280-017-3498-z. Epub 2017 Dec 11.

PMID:
29230503
37.

Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study.

Tanaka H, Nakatani E, Fukutomi Y, Sekiya K, Kaneda H, Iikura M, Yoshida M, Takahashi K, Tomii K, Nishikawa M, Kaneko N, Sugino Y, Shinkai M, Ueda T, Tanikawa Y, Shirai T, Hirabayashi M, Aoki T, Kato T, Iizuka K, Fujii M, Taniguchi M.

Allergy. 2018 May;73(5):1110-1118. doi: 10.1111/all.13374. Epub 2017 Dec 19.

PMID:
29197099
38.

Template-based quaternary structure prediction of proteins using enhanced profile-profile alignments.

Nakamura T, Oda T, Fukasawa Y, Tomii K.

Proteins. 2018 Mar;86 Suppl 1:274-282. doi: 10.1002/prot.25432. Epub 2017 Dec 5.

39.

Tyrosine phosphorylation of the GARU E3 ubiquitin ligase promotes gibberellin signalling by preventing GID1 degradation.

Nemoto K, Ramadan A, Arimura GI, Imai K, Tomii K, Shinozaki K, Sawasaki T.

Nat Commun. 2017 Oct 17;8(1):1004. doi: 10.1038/s41467-017-01005-5.

40.

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.

Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K.

J Thorac Oncol. 2017 Dec;12(12):1798-1805. doi: 10.1016/j.jtho.2017.08.022. Epub 2017 Sep 20.

41.

KRAS mutation-positive mucinous adenocarcinoma originating in the thymus.

Sakanoue I, Hamakawa H, Fujimoto D, Imai Y, Minami K, Tomii K, Takahashi Y.

J Thorac Dis. 2017 Aug;9(8):E694-E697. doi: 10.21037/jtd.2017.07.11.

42.

Successful Treatment of Herpes Simplex Virus (HSV)-1-associated Hemophagocytic Lymphohistiocytosis (HLH) with Acyclovir: A Case Report and Literature Review.

Yabushita T, Yoshioka S, Koba Y, Ono Y, Hiramoto N, Tabata S, Itou M, Shimizu N, Tomii K, Ishikawa T.

Intern Med. 2017 Nov 1;56(21):2919-2923. doi: 10.2169/internalmedicine.8490-16. Epub 2017 Sep 15.

43.

Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.

Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, Kohara N, Tomii K.

Ann Oncol. 2017 Sep 1;28(9):2318-2319. doi: 10.1093/annonc/mdx252. No abstract available.

PMID:
28911080
44.

Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.

Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, Nagata K, Nakagawa A, Kosaka Y, Otsuka K, Imai Y, Hamakawa H, Takahashi Y, Kokubo M, Tomii K.

Sci Rep. 2017 Sep 12;7(1):11373. doi: 10.1038/s41598-017-11949-9.

45.

Designing better diffracting crystals of biotin carboxyl carrier protein from Pyrococcus horikoshii by a mutation based on the crystal-packing propensity of amino acids.

Yamada KD, Kunishima N, Matsuura Y, Nakai K, Naitow H, Fukasawa Y, Tomii K.

Acta Crystallogr D Struct Biol. 2017 Sep 1;73(Pt 9):757-766. doi: 10.1107/S2059798317010932. Epub 2017 Aug 15.

46.

A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.

Fujimoto D, Morimoto T, Ito J, Sato Y, Ito M, Teraoka S, Otsuka K, Nagata K, Nakagawa A, Tomii K.

Lung Cancer. 2017 Sep;111:1-5. doi: 10.1016/j.lungcan.2017.06.008. Epub 2017 Jun 17.

PMID:
28838377
47.

Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.

Shiga Y, Murata D, Sugimoto A, Oshima Y, Tada M, Ishii-Watabe A, Imai K, Tomii K, Takeuchi T, Kagaya S, Sato A.

Mol Pharm. 2017 Sep 5;14(9):3025-3035. doi: 10.1021/acs.molpharmaceut.7b00221. Epub 2017 Aug 18.

PMID:
28763236
48.

Enteral Nutrition During Noninvasive Ventilation: We Should Go Deeper in the Investigation-Reply.

Kogo M, Nagata K, Morimoto T, Ito J, Sato Y, Teraoka S, Fujimoto D, Nakagawa A, Otsuka K, Tomii K.

Respir Care. 2017 Aug;62(8):1119-1120. doi: 10.4187/respcare.05684. No abstract available.

49.

Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity.

Sato Y, Fujimoto D, Morimoto T, Uehara K, Nagata K, Sakanoue I, Hamakawa H, Takahashi Y, Imai Y, Tomii K.

Respirology. 2017 Nov;22(8):1615-1621. doi: 10.1111/resp.13089. Epub 2017 Jun 13.

50.

Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature.

Mori R, Fujimoto D, Ito M, Tomii K.

Oncotarget. 2017 Jul 18;8(29):48521-48524. doi: 10.18632/oncotarget.17952. Review.

Supplemental Content

Support Center